MedPath

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

Phase 3
Completed
Conditions
Phenylketonuria (PKU)
Interventions
Drug: BMN165 40mg/day
Drug: BMN165 20mg/day
Drug: Placebo
Registration Number
NCT01889862
Lead Sponsor
BioMarin Pharmaceutical
Brief Summary

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.

Detailed Description

165-302 is a Phase 3, 4 Part, Randomized, Double-Blind, Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self Administered Subcutaneous Injections of BMN 165 by Adults With PKU.

This study is open only to adults who have been exposed to BMN165 in a previous study.

Study BMN 165-302 is a four-Part, Phase 3 study.

* Part 1: Open-label period

* Part 2: A Randomized, double-blind, placebo-controlled period of 8 weeks

* Part 3: Two sub-Parts to Part 3:- Part 3A - BMN 165 administered using vial and syringe during this open label period. Part 3B - BMN 165 administered using prefilled syringe during this open-label period.

* Part 4: A long-term, open-label extension period.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
215
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BMN165 40mg/dayBMN165 40mg/dayBMN165 40mg/day self-administered daily
BMN165 20mg/dayBMN165 20mg/dayBMN165 20mg/day self-administered daily
40 mg/day PlaceboPlacebo40 mg/day Placebo self-administered daily
20 mg/day PlaceboPlacebo20 mg/day Placebo self-administered daily
Primary Outcome Measures
NameTimeMethod
Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 2At Part 2 baseline and change from baseline at Part 2 week 8

Blood phe concentration in subjects previously exposed to BMN165 who were administered BMN165 20 or 40 mg/day compared with those who were administered a matching placebo.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in the Cognitive and Mood Symptoms Measured by ADHD Rating Scale (RS)-IV Inattention Subscale at Part 2At Part 2 baseline and change from baseline at Part 2 week 8

Attention deficit hyperactivity disorder rating scale IV (ADHD RS-IV) is investigator-rated, 9-item, inattention subscale score ranges from 0 to 27, with higher scores indicative of a greater degree of impairment and a baseline score \>9 indicative of a presence of symptoms.

Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 4At Part 4 week 57, 105, 161, 209 and 249

The long term effect of multiple dose levels of BMN165 on blood phe concentration in subjects who are administered BMN165 using pre-filled syringes.

Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS TMD at Part 2At Part 2 baseline and change from baseline at Part 2 week 8

Phenylketonuria (PKU) Total Mood Disturbance (TMD) Profile of Mood States (POMS)

PKU POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

Change From Baseline in the Cognitive and Mood Symptoms Measured by PKU POMS Confusion Subscale at Part 2At Part 2 baseline and change from baseline at Part 2 week 8

PKU POMS confusion mood domain (referred to as the confusion subscale) is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

Change From Baseline in the Cognitive and Mood Symptoms Measured by POMS TMD at Part 2At Part 2 baseline and change from baseline at Part 2 week 8

Full-length POMS TMD is self-rated, each item in the tool is rated using a five-point Likert scale: 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely).

Trial Locations

Locations (29)

University of South Florida

🇺🇸

Tampa, Florida, United States

UCSF Benioff Children's Hospital Oakland

🇺🇸

Oakland, California, United States

Cooper Health Systems

🇺🇸

Camden, New Jersey, United States

Vanderbilt Children's Hospital

🇺🇸

Nashville, Tennessee, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

Emory Universty, Department of Human Genetics, Division of Medical Genetics

🇺🇸

Atlanta, Georgia, United States

Ann and Robert H Lurie Children's Hospital of Chicago

🇺🇸

Chicago, Illinois, United States

Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

University of California, San Diego Clinical and Translational Research Institute

🇺🇸

La Jolla, California, United States

Children's Hospital Colorado

🇺🇸

Aurora, Colorado, United States

University of Florida Clinical Research Center

🇺🇸

Gainesville, Florida, United States

Indiana CTSI Clinical Research Center

🇺🇸

Indianapolis, Indiana, United States

University of Kentucky Medical Center

🇺🇸

Lexington, Kentucky, United States

University of Louisville, Kosair Charities Pediatric Clinical Research Unit

🇺🇸

Louisville, Kentucky, United States

Wayne State University Clinical Research Center at the Mott Center

🇺🇸

Detroit, Michigan, United States

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

University of Missouri Health Center

🇺🇸

Columbia, Missouri, United States

Washington University Center for Applied Research Sciences

🇺🇸

Saint Louis, Missouri, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Icahn School of Medicine at Mount Sinai Medical Center

🇺🇸

New York, New York, United States

Atlantic Health System - Morristown Medical Center

🇺🇸

Morristown, New Jersey, United States

Albany Medical Center

🇺🇸

Albany, New York, United States

University Hospitals Case Medical Center

🇺🇸

Cleveland, Ohio, United States

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

University of Texas Houston Medical School

🇺🇸

Houston, Texas, United States

University of Utah Hospital

🇺🇸

Salt Lake City, Utah, United States

University of Washinton

🇺🇸

Seattle, Washington, United States

St. Christopher's Hospital for Children

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath